CLINICAL RESEARCH SERVICES

临床研究服务(CRS)成立于1986年12月，作为一个共享资源，以促进 开发、实施和完成所有UPCI型临床研究。全球的一部分 用于临床试验支持的UPCI基础设施，CRS与方案审查协同工作 委员会(中华人民共和国)和数据安全和监测委员会(数据安全和监测委员会)；这三个实体都在运作 在临床研究监督委员会(CROC)的监督下。亚当·布鲁夫斯基医学博士， 临床调查副主任负责监督临床研究中心的工作。史蒂夫·马尔卡希担任董事， CRS，而BSN Holly Goe担任CRS副主任。 CRS是所有UPCI临床的监督、管理和监测的协调中心 研究活动。它为研究的发展和实施、内部评审委员会的提交和 处理中华人民共和国批准的试验、患者招募、研究协调以及样本和数据 为匹兹堡大学和UPMC进行癌症相关研究的所有研究人员提供的集合 癌症中心。CRS数据库临床试验管理应用程序(CTMA)保持最新 记录每项研究的状况，并促进及时提交所有必要的文件和 IRB修正案、学习更新表格、进度报告。数据安全监控信息， 严重不良事件、月报、IRB等通信。CRS持续增长 并适应癌症临床研究的科学、监管和财务挑战。

The Clinical Research Service (CRS) was established in December, 1986 as a shared resource to facilitate development, implementation, and completion of all UPCI clinical research studies. A part of the global UPCI infrastructure for clinical trial support, the CRS works in tandem with the Protocol Review Committees (PRC) and the Data Safety and Monitoring Committee (DSMC); all three entities function under the oversight of the Clinical Research Oversight Committee (CROC). Adam Brufsky, M.D., Ph.D., Associate Director for Clinical Investigation oversees the CRS. Steve Mulcahy, MS serves as Director, CRS while Holly Goe, BSN, serves as Associate Director, CRS. The CRS serves as the coordinating center for oversight, management, and monitoring for all UPCI clinical research activities. It provides assistance with study development and implementation, IRB submission and processing of PRC-approved trials, patient recruitment, study coordination, and specimen and data collection for all investigators conducting cancer-related studies at the University of Pittsburgh and UPMC Cancer Centers. The CRS database Clinical Trials Management Application (CTMA) maintains up to date documentation on the status of each study and facilitates timely submission of all required documents and amendments to the IRB, study renewal forms, progress reports. Data Safety Monitoring information, Serious Adverse Events, monthly reports, IRB and other correspondence. The CRS has continued to grow and adapt to the scientific, regulatory and financial challenges of cancer clinical research.